RenovoRx Reports Record Q1 Revenue, Advances Pancreatic Cancer Trial, Extends Cash Runway

summarizeSummary

RenovoRx reported strong Q1 2026 results with record revenue growth and significant progress in its TIGeR-PaC clinical trial, supported by a recent $10 million capital raise that extends its cash runway.

check_boxKey Events

• Record Q1 Revenue Growth

  Revenue increased 186% year-over-year to $563,000 for Q1 2026, representing over 50% of total 2025 revenue, driven by expanding commercial cancer centers and increased RenovoCath utilization.

• TIGeR-PaC Trial Nearing Full Enrollment

  The Phase III clinical trial for locally advanced pancreatic cancer (TIGeR-PaC) is 93% enrolled with 106 out of 114 patients randomized as of May 14, 2026. Enrollment is expected to close by the end of June 2026, with final data anticipated in mid-to-late 2027.

• Commercial Footprint Expansion

  Active commercial cancer centers doubled from 8 at year-end 2025 to 16 as of May 6, 2026. The company is targeting 36 active centers by year-end 2026 and has a pipeline of 32 additional centers.

• Strengthened Cash Position

  Cash and cash equivalents reached $12.4 million as of March 31, 2026, following a $10 million private placement in March 2026, which is expected to fund operations for at least the next 12 months.

auto_awesomeAnalysis

RenovoRx's Q1 2026 results demonstrate significant commercial traction for its RenovoCath device, with revenue more than doubling year-over-year and active cancer centers doubling since year-end 2025. The company also made substantial progress in its pivotal TIGeR-PaC clinical trial, nearing full patient enrollment. A recent $10 million private placement has bolstered its cash position, providing a runway for at least the next 12 months. While net losses increased, the strong operational execution and clinical milestones are critical for this development-stage life sciences company. The ongoing Nasdaq minimum bid price non-compliance remains a key risk.